Abstract: The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desaturase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids. In particular, the present invention provides ?3 destaurases, ?5 elongases and ?6 desaturases with novel activities. Also provided are methods and DNA constructs for transiently and/or stably transforming cells, particularly plant cells, with multiple genes.

Abstract: The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desaturase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids. In particular, the present invention provides ?3 desaturases, ?5 elongases and ?6 desaturases with novel activities. Also provided are methods and DNA constructs for transiently and/or stably transforming cells, particularly plant cells, with multiple genes.

Abstract: The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desaturase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids. In particular, the present invention provides ?3 destaurases, ?5 elongases and ?6 desaturases with novel activities. Also provided are methods and DNA constructs for transiently and/or stably transforming cells, particularly plant cells, with multiple genes.

Abstract: The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desaturase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids. In particular, the present invention provides ?3 destaurases, ?5 elongases and ?6 desaturases with novel activities. Also provided are methods and DNA constructs for transiently and/or stably transforming cells, particularly plant cells, with multiple genes.

Abstract: The present invention relates generally to the field of recombinant fatty acid synthesis, particularly in transgenic plants. The application describes genes involved in fatty acid synthesis and provides methods and vectors for the manipulation of fatty acid composition of plant oils. In particular, the invention provides constructs for achieving the integration of multiple heterologous genes involved in fatty acid synthesis into the plant genome, such that the resulting plants produce altered levels of polyunsaturated fatty acids. Also described are methods for enhancing the expression of fatty acid biosynthesis enzymes by co-expressing a silencing suppressor within the plant storage organ.

Abstract: A clamp apparatus is disclosed. The clamp apparatus includes a first half having a first end and a second end; a second half having a first end and a second end, the first and second halves being connected together at the first ends; and wherein the second end of the first half and the second end of the second half are flared outwardly away from a centerline of the clamp apparatus to receive a conductor therebetween.

Abstract: A biodegradable cleaning composition comprises one or more species of lactic acid bacteria, one or more species of Bacillus, water, and at least one additional element selected from the group consisting of at least one biodetergent, organic acid, diol, polyol, polymyxin, polysaccharide-lipid complex, fatty acid, monoterpene, sesquiterpene, preservative, essential oil, and carbon source. A biodegradable cleaning composition kit comprises at least one textile that has been treated with the biodegradable cleaning composition, wherein the treated textile is contained within an openable container.

Abstract: The present invention pertains to an inventive release mechanism for extracellular vesicle (EV)-mediated intracellular and intramembrane delivery of therapeutic polypeptides. More specifically, the invention relates to EVs comprising polypeptide constructs which comprise a therapeutic polypeptide releasably attached to an exosomal polypeptide. Furthermore, the present invention pertains to manufacturing methods, pharmaceutical compositions, medical uses and applications, and various other embodiments related to the inventive EVs.

Abstract: A pallet includes a plastic top deck and a bamboo bottom deck. The bamboo bottom deck includes bamboo boards made from bamboo strips layered together. Support blocks are coupled between the bamboo bottom deck and the plastic top deck, with a gap being formed therebetween for receiving a lifting member.

Abstract: The present invention relates to compositions for the delivery of molecules such as a peptide, a nucleic acid and/or a small molecule drug. In particular, the present invention relates to an extracellular vesicle (EV) loaded with a peptide, a nucleic acid and/or a small molecule drug, along with methods of producing said EV.

Abstract: The present invention pertains to an inventive release mechanism for extracellular vesicle (EV)-mediated intracellular and intramembrane delivery of therapeutic polypeptides. More specifically, the invention relates to EVs comprising polypeptide constructs which comprise a therapeutic polypeptide releasably attached to an exosomal polypeptide. Furthermore, the present invention pertains to manufacturing methods, pharmaceutical compositions, medical uses and applications, and various other embodiments related to the inventive EVs.

Abstract: Systems, computer program products, and methods for generating and maintaining source capability objects for application components. The systems, computer program products, and methods are configured to receive a request to initiate a development process for an application, where the request identifies one or more components of the application, and cause a user device to prompt a user to select, for each component of the application, one or more source capabilities from a plurality of source capabilities. The systems, computer program products, and methods are further configured to receive, from the user device and for each component of the application, the one or more source capabilities and to generate, for each component of the application, a source capability object including information identifying the one or more source capabilities for the component.

Abstract: Techniques for partitioning data flow operations between execution on a compute instance and an attached accelerator instance are described. A set of operations supported by the accelerator is obtained. A set of operations associated with the data flow is obtained. An operation in the set of operations associated with the data flow is identified based on the set of operations supported by the accelerator. The accelerator executes the first operation.

Abstract: In representative embodiments, systems and methods to calculate the likelihood that presented cryptographic key material is untrustworthy are disclosed. A predictive model based on a debasing condition and a dataset is created by evaluating the dataset relative to the debasing condition. For example, if certificate revocation is selected as the debasing condition, the dataset is analyzed to produce a predictive model that determines the likelihood that a presented certificate is untrustworthy based on similarity to already revoked certificates. The predictive model can include a supervised learning model like a logistic regression model or a deep neural network model. The system can be used in conjunction with existing security infrastructures or can be used as a separate infrastructure. Based on the likelihood score calculated by the model, a relying system can reject the cryptographic key material, accept the cryptographic key material or take other further action.

Abstract: A method of routing a first signal in a telecommunication network is disclosed. The telecommunication network comprises plural nodes and uses time-division multiple access (TDMA) frames, with each TDMA frame divided into time slots and each time slot is divided into subslots. The method includes the step of transmitting a first signal from an initiating node in a first subslot. The method further includes the step of receiving the first signal at other nodes in the network in the first subslot, wherein the first signal is retransmitted in a second subslot subsequent to the first subslot. An improvement in the method includes the step of preparing for the retransmission at least one of a time-dispersed first signal or time-dispersed algorithmically related first signal by two or more nodes via a controller.

Abstract: The present invention relates to conjugates formed from a cell-penetrating peptide carrier linked to a therapeutic molecule, wherein the peptide carrier is defined by specific domains and the therapeutic molecule is a nucleic acid formed of trinucleotide repeats. The present invention further relates to the use of such a conjugate in methods of treatment or as a medicament, especially in the treatment of trinucleotide repeat disorders such as myotonic dystrophy (DM1).

Abstract: Optimal GMSK training sequences are generated by applying a base sequence to the in-phase component of the even samples and rotating the base sequence by 2k-1 and applying the second sequence to the quadrature component of the odd samples. Using the optimal GMSK training sequence a channel estimate can be generated. Filtering the channel estimate converts the channel impulse response to one that can be used with a non-GMSK signal e.g. PSK or QAM.

Abstract: The present invention relates to linkers for connecting a carrier molecule to a therapeutic molecule to form a conjugate, in particular linkers formed of amino acids such as glutamic acid, succinic acid, and gamma-aminobutyric acid. The present invention further relates to a conjugate comprising a linker of the invention, and the use of said conjugate in the treatment of various diseases.

Abstract: Embodiments of the invention are directed to a system, method, or computer program product structured for determining platform stability and resiliency.

Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.